ALFREDO 22010112130140 Lap.KTI Bab7
54
DAFTAR PUSTAKA
1.
Setiati S, Alwi I, Sudoyo AW, Stiyohadi B, Syam AF. Buku ajar ilmu
penyakit dalam jilid I. VI. Jakarta: InternaPublishing; 2014:1132-53.
2.
Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, Simone GD, et
al. Heart disease and stroke statistics--2010 update: a report from the
American Heart Association. Circulation. 2010;121(7):e46-e215.
3.
Ri D. Profil Kesehatan Indonesia 2008. J Pers Soc Psychol. 2009;51(6):40.
4.
Lilly LS. Pathophysiology of heart disease: a collaborative project of medical
students and faculty. Vol V. V. (Lilly LS, ed.). Lippincott Williams &
Wilkins; 2011: 216-43.
5.
Koukouvou G, Kouidi E, Iacovides A, Konstantinidou E, Kaprinis G,
Deligiannis A. Quality of life, psychological and physiological changes
following exercise training in patients with chronic heart failure. J Rehabil
Med. 2004;36(1):36-41.
6.
van Tol BAF, Huijsmans RJ, Kroon DW, Schothorst M, Kwakkel G. Effects
of exercise training on cardiac performance, exercise capacity and quality of
life in patients with heart failure: a meta-analysis. Eur J Heart Fail.
2006;8(8):841-50.
7.
Garin O, Ribera A, Rajmil L, Valderas JM, Guillemin F, Revicki D, et al.
Assessing health-related quality of life in patients with heart failure: a
systematic, standardized comparison of available measures. Heart Fail Rev.
2014;19(3):359-67.
8.
Austin BA, Wang Y, Smith GL, Vaccarine V, Krumholz HM, McNamara
RL. Systolic function as a predictor of mortality and quality of life in longterm survivors with heart failure. Clin Cardiol. 2008;31(3):119-24.
9.
Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG,
Marburger CT, et al. Pathophysiological characterization of isolated diastolic
heart
failure
in
2002;288(17):2144.
comparison
to
systolic
heart
failure.
JAMA.
55
10.
Hobbs FDR, Kenkre JE, Roalfe AK, Davis RC, Hare R, Davies MK. Impact
of heart failure and left ventricular systolic dysfunction on quality of life: a
cross-sectional study comparing common chronic cardiac and medical
disorders
and
a
representative
adult
population.
Eur
Heart
J.
2002;23(23):1867-76.
11.
Fuster V, O’Rourke RA, Walsh R, Poole-Wilson P. Hurst’s the heart, 12th
edition. Vol 2007.; 2007:719-38.
12.
Fauci A, Braunwald E, Kasper D, Hauser S, Longo D, Jameson J, et al.
Harrison’s principles of internal medicine, 17th edition.; 2008:1443-54.
13.
Heart
failure
Risk
factors
-
Mayo
Clinic.
http://www.mayoclinic.org/diseases-conditions/heart-failure/basics/riskfactors/con-20029801. Accessed December 10, 2015.
14.
Kumar V, Abbas AK, Fausto N, Mitchell R. Robbins basic pathology, 8th
edition.; 2007:578-82.
15.
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et
al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines
for the Diagnosis and Management of Heart Failure in Adults A Report of the
American College of Cardiology Foundation/American Heart Association
Task Force on Practice Guidelines Developed . J Am Coll Cardiol.
2009;53(15):e1-e90.
16.
He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk
factors for congestive heart failure in US men and women: NHANES I
epidemiologic follow-up study. Arch Intern Med. 2001;161(7):996-1002.
17.
Doggrell SA. CHARMed – the effects of candesartan in heart failure. Expert
Opin Pharmacother. April 2005.
18.
Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR,
Rodeheffer RJ, et al. Burden of systolic and diastolic ventricular dysfunction
in the community: appreciating the scope of the heart failure epidemic. JAMA.
2003;289(2):194-202.
19.
Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, et al.
Relation of disease pathogenesis and risk factors to heart failure with
56
preserved or reduced ejection fraction: insights from the framingham heart
study of the national heart, lung, and blood institute. Circulation.
2009;119(24):3070-77.
20.
Russell SD, Saval MA, Robbins JL, Ellestad MH, Gottlieb SS, Handberg EM,
et al. New York Heart Association functional class predicts exercise
parameters in the current era. Am Heart J. 2009;158(4 Suppl):S24-S30.
21.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al.
2013 ACCF/AHA guideline for the management of heart failure: a report of
the American College of Cardiology Foundation/American Heart Association
Task Force on practice guidelines. Circulation. 2013;128(16):e240-e327.
22.
Madhok V, Falk G, Rogers A, Struthers AD, Sullivan FM, Fahey T, et al. The
accuracy of symptoms, signs and diagnostic tests in the diagnosis of left
ventricular dysfunction in primary care: a diagnostic accuracy systematic
review. BMC Fam Pract. 2008;9:56.
23.
Jimeno Sainz A, Gil V, Merino J, García M, Jordán A, Guerrero L, et al.
Validity of Framingham criteria as a clinical test for systolic heart failure. Rev
cĺnica espãola. 2006;206(10):495-98.
24.
Maestre A, Gil V, Gallego J, Aznar J, Mora A, Martín-Hidalgo A, et al.
Diagnostic accuracy of clinical criteria for identifying systolic and diastolic
heart failure: cross-sectional study. J Eval Clin Pract. 2009;15(1):55-61.
25.
Watson RD, Gibbs CR, Lip GY. ABC of heart failure. Clinical features and
complications. BMJ. 2000;320(7229):236-39.
26.
Wilkins LW, Tajik AJ, M.D., et al. Cardiovascular physiology concepts 2nd
ed. Lippincott Williams & Wilkins; 2013:205-13.
27.
Ciampi Q, Villari B. Role of echocardiography in diagnosis and risk
stratification in heart failure with left ventricular systolic dysfunction.
Cardiovasc Ultrasound. 2007;5:34.
28.
Naik MM, Diamond GA, Pai T, Soffer A, Siegel RJ. Correspondence of left
ventricular
ejection
fraction
determinations
from
two-dimensional
echocardiography, radionuclide angiography and contrast cineangiography. J
Am Coll Cardiol. 1995;25(4):937-42.
57
29.
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA,
et al. Recommendations for chamber quantification. Eur J Echocardiogr.
2006;7(2):79-108.
30.
Cella DF. Quality of life: concepts and definition. J Pain Symptom Manage.
1994;9(3):186-92.
31.
CDC - Concept - HRQOL. http://www.cdc.gov/hrqol/concept.htm. Accessed
January 15, 2016.
32.
Indonesia U, Suharsono T, Keperawatan FI, Magister P, Keperawatan I.
Universitas Indonesia .Dampak home based exercise training terhadap
kapasitas fungsional dan kualitas hidup pasien. 2011.
33.
Lam CL, Lauder IJ. The impact of chronic diseases on the health-related
quality of life (HRQOL) of Chinese patients in primary care. Fam Pract.
2000;17(2):159-166.
34.
Dunderdale K, Thompson DR, Miles JN V, Beer SF, Furze G. Quality-of-life
measurement in chronic heart failure: do we take account of the patient
perspective? Eur J Heart Fail. 2005;7(4):572-82.
35.
Dahlan MS. Statistik untuk kedokteran dan kesehatan. 6th ed. Jakarta:
Epidermiologi Indonesia; 2014:223-34
36.
Sakata Y, Shimokawa H. Epidemiology of heart failure in asia. Circ J.
2013;77(9):2209-17.
37.
WHO
|
Definition
of
an
older
or
elderly
person.
http://www.who.int/healthinfo/survey/ageingdefnolder/en/. Accessed May
30, 2016.
38.
Lam CSP. Heart failure in southeast asia: facts and numbers. ESC Hear Fail.
2015;2(2):46-9.
39.
Keteyian SJ, Piña IL, Hibner BA, Fleg JL. Clinical role of exercise training
in the management of patients with chronic heart failure. J Cardiopulm
Rehabil Prev. 30(2):67-76.
40.
Juenger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C, Herzog W, et
al. Health related quality of life in patients with congestive heart failure:
comparison with other chronic diseases and relation to functional variables.
58
Heart. 2002;87(3):235-41.
41.
Joseph SM, Novak E, Arnold SV, Jones PG, Khattak H, Platts AE, et al.
Comparable performance of the kansas city cardiomyopathy questionnaire in
patients with heart failure with preserved and reduced ejection fraction. Circ
Heart Fail. 2013;6(6):1139-46.
42.
Heo S, Lennie TA, Okoli C, Moser DK. Quality of life in patients with heart
failure: ask the patients. Heart Lung. 2009;38(2):100-08.
43.
Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM.
Trends in prevalence and outcome of heart failure with preserved ejection
fraction. N Engl J Med. 2006;355(3):251-59.
44.
Effect of enalapril on survival in patients with reduced left ventricular
ejection fractions and congestive heart failure. The SOLVD Investigators. N
Engl J Med. 1991;325(5):293-302.
45.
Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect
of carvedilol on survival in severe chronic heart failure. N Engl J Med.
2001;344(22):1651-58.
46.
Moss AJ, Zareba W, Hall WJ, Klein H, Wilver DJ, Dannom DS, et al.
Prophylactic implantation of a defibrillator in patients with myocardial
infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-83.
Lampiran 1. Ethical Clearance
Lampiran 2. Surat izin penelitian
Lampiran 3. Informed consent
Lampiran 4. Data hasil penelitian
No. Nama
(Akronim)
No. RM
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
C534490
C454763
C540902
C142510
C492011
C560053
C581213
C576319
C229017
C404533
C576368
C342953
C551953
C583000
C479650
C582527
C572396
C560723
C569782
C582841
C583150
C583145
C576780
C573745
C549228
C573292
C584647
C584019
C228963
C371070
C382344
C184998
Pu
Su
La
St
MZ
TD
SSp
SSb
SSm
Sj
SN
KD
IT
GT
Sn
Rb
Snn
KS
Tj
JS
Uw
Dj
NS
AS
Sr
SP
AN
DS
DY
Ag
ADL
Ms
LVEF
(dalam
%)
49
74
74
56
52
62
16
60
74
30
65
83
39
69
41
78
66
69
49
86
74
34
69
36
87
65
63
64
61
67
64
62
MLHFQ
dimensi
Fisik
4
1
3
9
6
13
11
20
1
32
26
7
5
6
1
6
21
13
6
14
28
16
8
6
9
16
22
8
18
17
25
4
MLHFQ
dimensi
Umum
6
6
5
11
3
14
7
26
9
26
24
7
14
7
13
3
14
13
12
7
30
13
3
16
13
16
23
4
12
20
28
3
MLHFQ
dimensi
Emosi
1
8
3
2
0
9
2
8
4
16
18
5
0
6
6
1
6
0
9
18
15
11
4
0
0
8
5
8
12
8
21
8
Skor
total
MLHFQ
11
15
11
22
9
36
20
54
14
74
68
19
19
19
20
10
41
26
27
39
73
40
15
22
22
40
50
20
47
45
74
15
Lampiran 5. Hasil analisis statistik SPSS versi 21
Jenis Kelamin
Frequency
Percent
Valid Percent
Cumulative
Percent
Valid
Perempuan
19
59,4
59,4
59,4
Laki-laki
13
40,6
40,6
100,0
Total
32
100,0
100,0
Umur
Frequency
Percent
Valid Percent
Cumulative
Percent
Valid
24
1
3,1
3,1
3,1
31
1
3,1
3,1
6,3
32
1
3,1
3,1
9,4
37
1
3,1
3,1
12,5
40
1
3,1
3,1
15,6
46
1
3,1
3,1
18,8
47
2
6,3
6,3
25,0
48
1
3,1
3,1
28,1
50
1
3,1
3,1
31,3
53
1
3,1
3,1
34,4
54
4
12,5
12,5
46,9
55
3
9,4
9,4
56,3
56
3
9,4
9,4
65,6
57
2
6,3
6,3
71,9
58
1
3,1
3,1
75,0
60
2
6,3
6,3
81,3
61
2
6,3
6,3
87,5
63
1
3,1
3,1
90,6
64
1
3,1
3,1
93,8
66
2
6,3
6,3
100,0
32
100,0
100,0
Total
NYHA
Frequency
Percent
Valid Percent
Cumulative
Percent
NYHA kelas I
15
46,9
46,9
46,9
NYHA kelas II
13
40,6
40,6
87,5
NYHA kelas III
4
12,5
12,5
100,0
32
100,0
100,0
Valid
Total
LVH
Frequency
Percent
Valid Percent
Cumulative
Percent
Valid
Tidak
12
37,5
37,5
37,5
Ya
20
62,5
62,5
100,0
Total
32
100,0
100,0
Diuretik
Frequency
Percent
Valid Percent
Cumulative
Percent
Valid
Tidak
12
37,5
37,5
37,5
Ya
20
62,5
62,5
100,0
Total
32
100,0
100,0
Beta Blocker
Frequency
Percent
Valid Percent
Cumulative
Percent
Valid
Tidak
16
50,0
50,0
50,0
Ya
16
50,0
50,0
100,0
Total
32
100,0
100,0
Ca channel Blocker
Frequency
Percent
Valid Percent
Cumulative
Percent
Tidak
Valid
Ya
Total
26
81,3
81,3
81,3
6
18,8
18,8
100,0
32
100,0
100,0
Digoxin
Frequency
Percent
Valid Percent
Cumulative
Percent
Tidak
Valid
Ya
Total
25
78,1
78,1
78,1
7
21,9
21,9
100,0
32
100,0
100,0
Antiplatelet
Frequency
Percent
Valid Percent
Cumulative
Percent
Valid
Tidak
19
59,4
59,4
59,4
Ya
13
40,6
40,6
100,0
Total
32
100,0
100,0
Nitrat
Frequency
Percent
Valid Percent
Cumulative
Percent
Valid
Tidak
14
43,8
43,8
43,8
Ya
18
56,3
56,3
100,0
Total
32
100,0
100,0
ACE inhibitor
Frequency
Percent
Valid Percent
Cumulative
Percent
Valid
Tidak
19
59,4
59,4
59,4
Ya
13
40,6
40,6
100,0
Total
32
100,0
100,0
Trombolitik
Frequency
Percent
Valid Percent
Cumulative
Percent
Valid
Tidak
16
50,0
50,0
50,0
Ya
16
50,0
50,0
100,0
Total
32
100,0
100,0
Statistics
Umur
Valid
32
N
Missing
0
Mean
52,41
Median
55,00
Mode
54
Std. Deviation
10,191
Minimum
24
Maximum
66
Case Processing Summary
Cases
Valid
N
Missing
Percent
N
Total
Percent
N
Percent
LVEF
32
100,0%
0
0,0%
32
100,0%
Dimensi Fisik
32
100,0%
0
0,0%
32
100,0%
Dimensi Umum
32
100,0%
0
0,0%
32
100,0%
Dimensi Emosi
32
100,0%
0
0,0%
32
100,0%
MLHFQ total
32
100,0%
0
0,0%
32
100,0%
Descriptives
Statistic
Mean
LVEF
60,56
95% Confidence Interval for
Lower Bound
54,53
Mean
Upper Bound
66,59
5% Trimmed Mean
61,30
Median
64,00
Variance
Std. Deviation
279,738
16,725
Std. Error
2,957
Minimum
16
Maximum
87
Range
71
Interquartile Range
23
Skewness
-0,796
0,414
Kurtosis
0,431
0,809
Mean
11,94
1,503
95% Confidence Interval for
Lower Bound
8,87
Mean
Upper Bound
15,00
5% Trimmed Mean
11,51
Median
9,00
Variance
Dimensi Fisik
72,319
Std. Deviation
8,504
Minimum
1
Maximum
32
Range
31
Interquartile Range
12
Skewness
Kurtosis
Mean
-0,412
0,809
12,81
1,389
Lower Bound
9,98
Mean
Upper Bound
15,65
5% Trimmed Mean
12,44
Median
12,50
61,770
Std. Deviation
7,859
Minimum
3
Maximum
30
Range
27
Interquartile Range
10
Skewness
Kurtosis
Mean
Dimensi Emosi
0,414
95% Confidence Interval for
Variance
Dimensi Umum
0,711
0,717
0,414
-0,434
0,809
6,94
1,029
95% Confidence Interval for
Lower Bound
4,84
Mean
Upper Bound
9,04
5% Trimmed Mean
6,60
Median
6,00
Variance
Std. Deviation
33,867
5,820
Minimum
0
Maximum
21
Range
21
Interquartile Range
7
Skewness
Kurtosis
Mean
0,414
-0,013
0,809
31,78
3,531
95% Confidence Interval for
Lower Bound
24,58
Mean
Upper Bound
38,98
5% Trimmed Mean
30,68
Median
22,00
Variance
MLHFQ total
0,789
398,886
Std. Deviation
19,972
Minimum
9
Maximum
74
Range
65
Interquartile Range
28
Skewness
Kurtosis
0,946
0,414
-0,166
0,809
Tests of Normality
Shapiro-Wilk
Statistic
df
Sig.
LVEF
0,942
32
0,085
Umur
0,890
32
0,004
NYHA
0,769
32
0,000
a. Lilliefors Significance Correction
Correlations
LVEF
Pearson Correlation
LVEF
Pearson Correlation
Sig. (2-tailed)
N
Dimensi Emosi
Dimensi Emosi
MLHFQ total
-0,057
0,099
-0,046
0,757
0,589
0,804
32
32
32
32
-0,057
1
0,669**
0,951**
0,000
,000
0,757
32
32
32
32
Pearson Correlation
0,099
**
1
0,795**
Sig. (2-tailed)
0,589
0,000
32
32
32
32
-0,046
0,951**
0,795**
1
0,804
0,000
0,000
32
32
32
N
Pearson Correlation
MLHFQ total
1
Sig. (2-tailed)
N
Dimensi Fisik
Dimensi Fisik
Sig. (2-tailed)
N
**. Correlation is significant at the 0.01 level (2-tailed).
0,669
0,000
32
Lampiran 6. Kuesioner Minnesota Living with Heart Failure
Lampiran 7. Dokumentasi penelitian
Lampiran 8. Biodata Mahasiswa
BIODATA MAHASISWA
Identitas
Nama
: Alfredo
NIM
: 22010112130140
Tempat/tanggal lahir : Jakarta, 10 Maret 1994
Jenis kelamin
: laki-laki
Alamat
: Jl. Gondang Timur IV No. 66B, Semarang
Nomor HP
: 087887760808
e-mail
: paulusalfredo@gmail.com
Riwayat Pendidikan Formal
1. SD
: SD San Marino, Jakarta.
Lulus tahun
: 2006
2. SMP
: SMP San Marino, Jakarta.
Lulus tahun
: 2009
3. SMA
: SMAN 2 Jakarta.
Lulus tahun
: 2012
4. FK UNDIP : Masuk tahun : 2012
DAFTAR PUSTAKA
1.
Setiati S, Alwi I, Sudoyo AW, Stiyohadi B, Syam AF. Buku ajar ilmu
penyakit dalam jilid I. VI. Jakarta: InternaPublishing; 2014:1132-53.
2.
Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, Simone GD, et
al. Heart disease and stroke statistics--2010 update: a report from the
American Heart Association. Circulation. 2010;121(7):e46-e215.
3.
Ri D. Profil Kesehatan Indonesia 2008. J Pers Soc Psychol. 2009;51(6):40.
4.
Lilly LS. Pathophysiology of heart disease: a collaborative project of medical
students and faculty. Vol V. V. (Lilly LS, ed.). Lippincott Williams &
Wilkins; 2011: 216-43.
5.
Koukouvou G, Kouidi E, Iacovides A, Konstantinidou E, Kaprinis G,
Deligiannis A. Quality of life, psychological and physiological changes
following exercise training in patients with chronic heart failure. J Rehabil
Med. 2004;36(1):36-41.
6.
van Tol BAF, Huijsmans RJ, Kroon DW, Schothorst M, Kwakkel G. Effects
of exercise training on cardiac performance, exercise capacity and quality of
life in patients with heart failure: a meta-analysis. Eur J Heart Fail.
2006;8(8):841-50.
7.
Garin O, Ribera A, Rajmil L, Valderas JM, Guillemin F, Revicki D, et al.
Assessing health-related quality of life in patients with heart failure: a
systematic, standardized comparison of available measures. Heart Fail Rev.
2014;19(3):359-67.
8.
Austin BA, Wang Y, Smith GL, Vaccarine V, Krumholz HM, McNamara
RL. Systolic function as a predictor of mortality and quality of life in longterm survivors with heart failure. Clin Cardiol. 2008;31(3):119-24.
9.
Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG,
Marburger CT, et al. Pathophysiological characterization of isolated diastolic
heart
failure
in
2002;288(17):2144.
comparison
to
systolic
heart
failure.
JAMA.
55
10.
Hobbs FDR, Kenkre JE, Roalfe AK, Davis RC, Hare R, Davies MK. Impact
of heart failure and left ventricular systolic dysfunction on quality of life: a
cross-sectional study comparing common chronic cardiac and medical
disorders
and
a
representative
adult
population.
Eur
Heart
J.
2002;23(23):1867-76.
11.
Fuster V, O’Rourke RA, Walsh R, Poole-Wilson P. Hurst’s the heart, 12th
edition. Vol 2007.; 2007:719-38.
12.
Fauci A, Braunwald E, Kasper D, Hauser S, Longo D, Jameson J, et al.
Harrison’s principles of internal medicine, 17th edition.; 2008:1443-54.
13.
Heart
failure
Risk
factors
-
Mayo
Clinic.
http://www.mayoclinic.org/diseases-conditions/heart-failure/basics/riskfactors/con-20029801. Accessed December 10, 2015.
14.
Kumar V, Abbas AK, Fausto N, Mitchell R. Robbins basic pathology, 8th
edition.; 2007:578-82.
15.
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et
al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines
for the Diagnosis and Management of Heart Failure in Adults A Report of the
American College of Cardiology Foundation/American Heart Association
Task Force on Practice Guidelines Developed . J Am Coll Cardiol.
2009;53(15):e1-e90.
16.
He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk
factors for congestive heart failure in US men and women: NHANES I
epidemiologic follow-up study. Arch Intern Med. 2001;161(7):996-1002.
17.
Doggrell SA. CHARMed – the effects of candesartan in heart failure. Expert
Opin Pharmacother. April 2005.
18.
Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR,
Rodeheffer RJ, et al. Burden of systolic and diastolic ventricular dysfunction
in the community: appreciating the scope of the heart failure epidemic. JAMA.
2003;289(2):194-202.
19.
Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, et al.
Relation of disease pathogenesis and risk factors to heart failure with
56
preserved or reduced ejection fraction: insights from the framingham heart
study of the national heart, lung, and blood institute. Circulation.
2009;119(24):3070-77.
20.
Russell SD, Saval MA, Robbins JL, Ellestad MH, Gottlieb SS, Handberg EM,
et al. New York Heart Association functional class predicts exercise
parameters in the current era. Am Heart J. 2009;158(4 Suppl):S24-S30.
21.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al.
2013 ACCF/AHA guideline for the management of heart failure: a report of
the American College of Cardiology Foundation/American Heart Association
Task Force on practice guidelines. Circulation. 2013;128(16):e240-e327.
22.
Madhok V, Falk G, Rogers A, Struthers AD, Sullivan FM, Fahey T, et al. The
accuracy of symptoms, signs and diagnostic tests in the diagnosis of left
ventricular dysfunction in primary care: a diagnostic accuracy systematic
review. BMC Fam Pract. 2008;9:56.
23.
Jimeno Sainz A, Gil V, Merino J, García M, Jordán A, Guerrero L, et al.
Validity of Framingham criteria as a clinical test for systolic heart failure. Rev
cĺnica espãola. 2006;206(10):495-98.
24.
Maestre A, Gil V, Gallego J, Aznar J, Mora A, Martín-Hidalgo A, et al.
Diagnostic accuracy of clinical criteria for identifying systolic and diastolic
heart failure: cross-sectional study. J Eval Clin Pract. 2009;15(1):55-61.
25.
Watson RD, Gibbs CR, Lip GY. ABC of heart failure. Clinical features and
complications. BMJ. 2000;320(7229):236-39.
26.
Wilkins LW, Tajik AJ, M.D., et al. Cardiovascular physiology concepts 2nd
ed. Lippincott Williams & Wilkins; 2013:205-13.
27.
Ciampi Q, Villari B. Role of echocardiography in diagnosis and risk
stratification in heart failure with left ventricular systolic dysfunction.
Cardiovasc Ultrasound. 2007;5:34.
28.
Naik MM, Diamond GA, Pai T, Soffer A, Siegel RJ. Correspondence of left
ventricular
ejection
fraction
determinations
from
two-dimensional
echocardiography, radionuclide angiography and contrast cineangiography. J
Am Coll Cardiol. 1995;25(4):937-42.
57
29.
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA,
et al. Recommendations for chamber quantification. Eur J Echocardiogr.
2006;7(2):79-108.
30.
Cella DF. Quality of life: concepts and definition. J Pain Symptom Manage.
1994;9(3):186-92.
31.
CDC - Concept - HRQOL. http://www.cdc.gov/hrqol/concept.htm. Accessed
January 15, 2016.
32.
Indonesia U, Suharsono T, Keperawatan FI, Magister P, Keperawatan I.
Universitas Indonesia .Dampak home based exercise training terhadap
kapasitas fungsional dan kualitas hidup pasien. 2011.
33.
Lam CL, Lauder IJ. The impact of chronic diseases on the health-related
quality of life (HRQOL) of Chinese patients in primary care. Fam Pract.
2000;17(2):159-166.
34.
Dunderdale K, Thompson DR, Miles JN V, Beer SF, Furze G. Quality-of-life
measurement in chronic heart failure: do we take account of the patient
perspective? Eur J Heart Fail. 2005;7(4):572-82.
35.
Dahlan MS. Statistik untuk kedokteran dan kesehatan. 6th ed. Jakarta:
Epidermiologi Indonesia; 2014:223-34
36.
Sakata Y, Shimokawa H. Epidemiology of heart failure in asia. Circ J.
2013;77(9):2209-17.
37.
WHO
|
Definition
of
an
older
or
elderly
person.
http://www.who.int/healthinfo/survey/ageingdefnolder/en/. Accessed May
30, 2016.
38.
Lam CSP. Heart failure in southeast asia: facts and numbers. ESC Hear Fail.
2015;2(2):46-9.
39.
Keteyian SJ, Piña IL, Hibner BA, Fleg JL. Clinical role of exercise training
in the management of patients with chronic heart failure. J Cardiopulm
Rehabil Prev. 30(2):67-76.
40.
Juenger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C, Herzog W, et
al. Health related quality of life in patients with congestive heart failure:
comparison with other chronic diseases and relation to functional variables.
58
Heart. 2002;87(3):235-41.
41.
Joseph SM, Novak E, Arnold SV, Jones PG, Khattak H, Platts AE, et al.
Comparable performance of the kansas city cardiomyopathy questionnaire in
patients with heart failure with preserved and reduced ejection fraction. Circ
Heart Fail. 2013;6(6):1139-46.
42.
Heo S, Lennie TA, Okoli C, Moser DK. Quality of life in patients with heart
failure: ask the patients. Heart Lung. 2009;38(2):100-08.
43.
Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM.
Trends in prevalence and outcome of heart failure with preserved ejection
fraction. N Engl J Med. 2006;355(3):251-59.
44.
Effect of enalapril on survival in patients with reduced left ventricular
ejection fractions and congestive heart failure. The SOLVD Investigators. N
Engl J Med. 1991;325(5):293-302.
45.
Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect
of carvedilol on survival in severe chronic heart failure. N Engl J Med.
2001;344(22):1651-58.
46.
Moss AJ, Zareba W, Hall WJ, Klein H, Wilver DJ, Dannom DS, et al.
Prophylactic implantation of a defibrillator in patients with myocardial
infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-83.
Lampiran 1. Ethical Clearance
Lampiran 2. Surat izin penelitian
Lampiran 3. Informed consent
Lampiran 4. Data hasil penelitian
No. Nama
(Akronim)
No. RM
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
C534490
C454763
C540902
C142510
C492011
C560053
C581213
C576319
C229017
C404533
C576368
C342953
C551953
C583000
C479650
C582527
C572396
C560723
C569782
C582841
C583150
C583145
C576780
C573745
C549228
C573292
C584647
C584019
C228963
C371070
C382344
C184998
Pu
Su
La
St
MZ
TD
SSp
SSb
SSm
Sj
SN
KD
IT
GT
Sn
Rb
Snn
KS
Tj
JS
Uw
Dj
NS
AS
Sr
SP
AN
DS
DY
Ag
ADL
Ms
LVEF
(dalam
%)
49
74
74
56
52
62
16
60
74
30
65
83
39
69
41
78
66
69
49
86
74
34
69
36
87
65
63
64
61
67
64
62
MLHFQ
dimensi
Fisik
4
1
3
9
6
13
11
20
1
32
26
7
5
6
1
6
21
13
6
14
28
16
8
6
9
16
22
8
18
17
25
4
MLHFQ
dimensi
Umum
6
6
5
11
3
14
7
26
9
26
24
7
14
7
13
3
14
13
12
7
30
13
3
16
13
16
23
4
12
20
28
3
MLHFQ
dimensi
Emosi
1
8
3
2
0
9
2
8
4
16
18
5
0
6
6
1
6
0
9
18
15
11
4
0
0
8
5
8
12
8
21
8
Skor
total
MLHFQ
11
15
11
22
9
36
20
54
14
74
68
19
19
19
20
10
41
26
27
39
73
40
15
22
22
40
50
20
47
45
74
15
Lampiran 5. Hasil analisis statistik SPSS versi 21
Jenis Kelamin
Frequency
Percent
Valid Percent
Cumulative
Percent
Valid
Perempuan
19
59,4
59,4
59,4
Laki-laki
13
40,6
40,6
100,0
Total
32
100,0
100,0
Umur
Frequency
Percent
Valid Percent
Cumulative
Percent
Valid
24
1
3,1
3,1
3,1
31
1
3,1
3,1
6,3
32
1
3,1
3,1
9,4
37
1
3,1
3,1
12,5
40
1
3,1
3,1
15,6
46
1
3,1
3,1
18,8
47
2
6,3
6,3
25,0
48
1
3,1
3,1
28,1
50
1
3,1
3,1
31,3
53
1
3,1
3,1
34,4
54
4
12,5
12,5
46,9
55
3
9,4
9,4
56,3
56
3
9,4
9,4
65,6
57
2
6,3
6,3
71,9
58
1
3,1
3,1
75,0
60
2
6,3
6,3
81,3
61
2
6,3
6,3
87,5
63
1
3,1
3,1
90,6
64
1
3,1
3,1
93,8
66
2
6,3
6,3
100,0
32
100,0
100,0
Total
NYHA
Frequency
Percent
Valid Percent
Cumulative
Percent
NYHA kelas I
15
46,9
46,9
46,9
NYHA kelas II
13
40,6
40,6
87,5
NYHA kelas III
4
12,5
12,5
100,0
32
100,0
100,0
Valid
Total
LVH
Frequency
Percent
Valid Percent
Cumulative
Percent
Valid
Tidak
12
37,5
37,5
37,5
Ya
20
62,5
62,5
100,0
Total
32
100,0
100,0
Diuretik
Frequency
Percent
Valid Percent
Cumulative
Percent
Valid
Tidak
12
37,5
37,5
37,5
Ya
20
62,5
62,5
100,0
Total
32
100,0
100,0
Beta Blocker
Frequency
Percent
Valid Percent
Cumulative
Percent
Valid
Tidak
16
50,0
50,0
50,0
Ya
16
50,0
50,0
100,0
Total
32
100,0
100,0
Ca channel Blocker
Frequency
Percent
Valid Percent
Cumulative
Percent
Tidak
Valid
Ya
Total
26
81,3
81,3
81,3
6
18,8
18,8
100,0
32
100,0
100,0
Digoxin
Frequency
Percent
Valid Percent
Cumulative
Percent
Tidak
Valid
Ya
Total
25
78,1
78,1
78,1
7
21,9
21,9
100,0
32
100,0
100,0
Antiplatelet
Frequency
Percent
Valid Percent
Cumulative
Percent
Valid
Tidak
19
59,4
59,4
59,4
Ya
13
40,6
40,6
100,0
Total
32
100,0
100,0
Nitrat
Frequency
Percent
Valid Percent
Cumulative
Percent
Valid
Tidak
14
43,8
43,8
43,8
Ya
18
56,3
56,3
100,0
Total
32
100,0
100,0
ACE inhibitor
Frequency
Percent
Valid Percent
Cumulative
Percent
Valid
Tidak
19
59,4
59,4
59,4
Ya
13
40,6
40,6
100,0
Total
32
100,0
100,0
Trombolitik
Frequency
Percent
Valid Percent
Cumulative
Percent
Valid
Tidak
16
50,0
50,0
50,0
Ya
16
50,0
50,0
100,0
Total
32
100,0
100,0
Statistics
Umur
Valid
32
N
Missing
0
Mean
52,41
Median
55,00
Mode
54
Std. Deviation
10,191
Minimum
24
Maximum
66
Case Processing Summary
Cases
Valid
N
Missing
Percent
N
Total
Percent
N
Percent
LVEF
32
100,0%
0
0,0%
32
100,0%
Dimensi Fisik
32
100,0%
0
0,0%
32
100,0%
Dimensi Umum
32
100,0%
0
0,0%
32
100,0%
Dimensi Emosi
32
100,0%
0
0,0%
32
100,0%
MLHFQ total
32
100,0%
0
0,0%
32
100,0%
Descriptives
Statistic
Mean
LVEF
60,56
95% Confidence Interval for
Lower Bound
54,53
Mean
Upper Bound
66,59
5% Trimmed Mean
61,30
Median
64,00
Variance
Std. Deviation
279,738
16,725
Std. Error
2,957
Minimum
16
Maximum
87
Range
71
Interquartile Range
23
Skewness
-0,796
0,414
Kurtosis
0,431
0,809
Mean
11,94
1,503
95% Confidence Interval for
Lower Bound
8,87
Mean
Upper Bound
15,00
5% Trimmed Mean
11,51
Median
9,00
Variance
Dimensi Fisik
72,319
Std. Deviation
8,504
Minimum
1
Maximum
32
Range
31
Interquartile Range
12
Skewness
Kurtosis
Mean
-0,412
0,809
12,81
1,389
Lower Bound
9,98
Mean
Upper Bound
15,65
5% Trimmed Mean
12,44
Median
12,50
61,770
Std. Deviation
7,859
Minimum
3
Maximum
30
Range
27
Interquartile Range
10
Skewness
Kurtosis
Mean
Dimensi Emosi
0,414
95% Confidence Interval for
Variance
Dimensi Umum
0,711
0,717
0,414
-0,434
0,809
6,94
1,029
95% Confidence Interval for
Lower Bound
4,84
Mean
Upper Bound
9,04
5% Trimmed Mean
6,60
Median
6,00
Variance
Std. Deviation
33,867
5,820
Minimum
0
Maximum
21
Range
21
Interquartile Range
7
Skewness
Kurtosis
Mean
0,414
-0,013
0,809
31,78
3,531
95% Confidence Interval for
Lower Bound
24,58
Mean
Upper Bound
38,98
5% Trimmed Mean
30,68
Median
22,00
Variance
MLHFQ total
0,789
398,886
Std. Deviation
19,972
Minimum
9
Maximum
74
Range
65
Interquartile Range
28
Skewness
Kurtosis
0,946
0,414
-0,166
0,809
Tests of Normality
Shapiro-Wilk
Statistic
df
Sig.
LVEF
0,942
32
0,085
Umur
0,890
32
0,004
NYHA
0,769
32
0,000
a. Lilliefors Significance Correction
Correlations
LVEF
Pearson Correlation
LVEF
Pearson Correlation
Sig. (2-tailed)
N
Dimensi Emosi
Dimensi Emosi
MLHFQ total
-0,057
0,099
-0,046
0,757
0,589
0,804
32
32
32
32
-0,057
1
0,669**
0,951**
0,000
,000
0,757
32
32
32
32
Pearson Correlation
0,099
**
1
0,795**
Sig. (2-tailed)
0,589
0,000
32
32
32
32
-0,046
0,951**
0,795**
1
0,804
0,000
0,000
32
32
32
N
Pearson Correlation
MLHFQ total
1
Sig. (2-tailed)
N
Dimensi Fisik
Dimensi Fisik
Sig. (2-tailed)
N
**. Correlation is significant at the 0.01 level (2-tailed).
0,669
0,000
32
Lampiran 6. Kuesioner Minnesota Living with Heart Failure
Lampiran 7. Dokumentasi penelitian
Lampiran 8. Biodata Mahasiswa
BIODATA MAHASISWA
Identitas
Nama
: Alfredo
NIM
: 22010112130140
Tempat/tanggal lahir : Jakarta, 10 Maret 1994
Jenis kelamin
: laki-laki
Alamat
: Jl. Gondang Timur IV No. 66B, Semarang
Nomor HP
: 087887760808
: paulusalfredo@gmail.com
Riwayat Pendidikan Formal
1. SD
: SD San Marino, Jakarta.
Lulus tahun
: 2006
2. SMP
: SMP San Marino, Jakarta.
Lulus tahun
: 2009
3. SMA
: SMAN 2 Jakarta.
Lulus tahun
: 2012
4. FK UNDIP : Masuk tahun : 2012